Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 0.1774 |
| Open | 0.1721 |
| Bid | 0.1650 x 2900 |
| Ask | 0.1700 x 900 |
| Day's range | 0.1630 - 0.1753 |
| 52-week range | 0.1500 - 1.1100 |
| Volume | |
| Avg. volume | 950,679 |
| Market cap | 21.897M |
| Beta (5Y monthly) | 1.98 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3120 |
| Earnings date | 10 Nov 2022 - 14 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.00 |
- Zacks
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -16.67% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Corcept (CORT) Posts OS Data from Phase II Ovarian Cancer Study
Corcept (CORT) posts overall survival data from a phase II study evaluating relacorilant plus nab-paclitaxel for treating recurrent platinum-resistant ovarian cancer.
© 2022 Yahoo. All rights reserved.
